• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    electroCore Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    9/6/24 5:05:25 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email
    false 0001560258 0001560258 2024-09-03 2024-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported)

    September 3, 2024

     

    electroCore, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38538   20-3454976

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    200 Forge Way, Suite 205

    Rockaway, NJ 07866

     (Address of principal executive offices and zip code)

     

    (973) 290-0097

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Title of each class  

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, Par Value $0.001 Per Share

      ECOR   The NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Retirement of Brian M. Posner as Chief Financial Officer

     

    On September 3, 2024, the Chief Financial Officer of electroCore, Inc. (the “Company”), Brian M. Posner, informed the Board of Directors (the “Board”) of the Company that he will be retiring effective as of October 4, 2024 for personal and family reasons. It is expected that Mr. Posner and the Company will enter into an agreement pursuant to which Mr. Posner will provide financial and accounting consulting services to the Company on an hourly basis for 12 months after the effective date of his retirement, subject to potential extension upon mutual agreement.

     

    Appointment of Joshua S. Lev as Chief Financial Officer

     

    On September 3, 2024, the Board appointed Joshua S. Lev, as Chief Financial Officer of the Company, effective as of Mr. Posner’s retirement on October 4, 2024.

     

    Mr. Lev, age 40, has served as the Chief Strategy Officer of the Company since January 2022, previously having served as VP of Business Development, Strategy and Financial Planning since February 2020. Prior to joining the Company, Mr. Lev had over 15 years of experience in the financial services industry as an investment banker and investor focusing on emerging growth companies. From 2011 to February 2020, Mr. Lev served as Director of Business Development at Wellfleet Partners, Inc. focusing on capital raising, M&A, strategic transactions and institutional client relations. From March 2014 through February 2020, he was also a co-founder of Aracle Capital, LLC, an investment firm with a focus on early-stage and emerging-growth companies. Mr. Lev received an M.B.A. from the University of North Carolina’s Kenan-Flagler Business School and a B.S. in Business & Management from the Sy Syms School of Business at Yeshiva University.

     

    In connection with his appointment as Chief Financial Officer, the Company and Mr. Lev entered into an amendment (the “Offer Letter Amendment”) to the offer letter dated January 29, 2020 (the “Lev Offer Letter”) pursuant to which, effective as of October 4, 2024, he will receive an annual base salary of $415,000, subject to periodic review and adjustment by the Company, and will be eligible for a discretionary annual bonus of up to 40 percent of the annual base salary upon achievement of certain individual and company goals. Mr. Lev is also eligible to continue receiving healthcare benefits as may be provided from time to time by the Company to its employees generally, to participate in a 401(k) plan and to receive paid time off annually in accordance with the Company’s policies in effect from time to time. Pursuant to the Offer Letter Amendment, Mr. Lev will be covered by the Company’s Executive Severance Policy, as such policy may be in effect from time to time; provided that in connection with the appointment of Mr. Lev as Chief Financial Officer effective October 4, 2024, the Company agreed to (i) increase the severance period for Mr. Lev under the Executive Severance Policy from six months to 12 months and (ii) the severance multiple (as defined in the Executive Severance Policy) payable to Mr. Lev shall be 1.0. Additionally, Mr. Lev and the Company have entered into the Company’s standard form of indemnification agreement for directors and executive officers.

     

    The foregoing descriptions of the Lev Offer Letter and the Offer Letter Amendment are incomplete and are qualified in their entirety by reference to the full text of the Lev Offer Letter and Offer Letter Amendment, which are attached hereto as Exhibits 10.1 and 10.2 and incorporated herein by reference.

     

    There are no arrangements or understandings between Mr. Lev and any other persons pursuant to which he was appointed as Chief Financial Officer. There are also no family relationships between Mr. Lev and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     

     

     

      

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On September 3, 2024, the Company held its Annual Meeting (the “Meeting”). The total number of shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company entitled to vote at the Meeting was 6,446,866 and there were present, in person or by proxy, 3,366,675 shares of Common Stock, which constituted a quorum for the Meeting. The matters voted upon and the results of the vote were as follows:

     

    Proposal 1: Election of two Class III Director to the Board of Directors for a three-year term of office expiring at the 2027 Annual Meeting of Stockholders.

     

    The following directors were elected to a three-year term of office expiring at the 2027 Annual Meeting of Stockholders:

     

    NOMINEE 

    FOR

    (#)

     

    FOR

    (%) 

     

    AGAINST

    (#)

     

    AGAINST

    (%)

      BROKER NON-VOTES
    John P. Gandolfo  1,822,264   96.05%  34,608  1.82%  1,469,414
    Charles S. Theofilos, M.D  1,839,298   96.95%  28,998  1.53%  1,469,414

     

    Proposal 2: Ratification of Appointment of Marcum LLP as Independent Registered Public Accounting Firm.

     

    A proposal to ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2024, was adopted with the votes shown:

     

    FOR   AGAINST   ABSTAIN  

    BROKER

    NON-VOTES

    3,279,990   33,819   52,866   n/a

     

     

     

     

    Proposal 3: Approval, by non-binding advisory vote, of the resolution approving named executive officer compensation.

     

    The compensation of the Company’s named executive officers was approved, by a non-binding advisory vote, as follows:

     

    FOR   AGAINST   ABSTAIN  

    BROKER

    NON-VOTES

    1,527,076   328,210   41,975   1,469,414

     

    Proposal 4: Approval, by non-binding advisory vote, of the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation.

     

    1 YEAR   2 YEARS   3 YEARS   ABSTAIN   BROKER NON-VOTES
    1,499,911   85,159   286,527   25,664   1,469,414

     

    In accordance with the voting results on this proposal which sets forth the preference of a majority of the Company’s stockholders, the board of directors has determined that the Company shall hold an advisory vote on executive compensation every year until the next required say-on-frequency vote.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Description
    10.1   Offer Letter by and between the Company and Joshua Lev, dated as of January 29, 2020.
    10.2   Amendment to the Offer Letter by and between the Company and Joshua Lev, dated as of September 3, 2024.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    September 6, 2024 electroCore, Inc.
       

    /s/ Brian M. Posner

      Brian M. Posner
      Chief Financial Officer

     

     

    Get the next $ECOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    SEC Filings

    View All

    electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - electroCore, Inc. (0001560258) (Filer)

    1/20/26 4:05:52 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by electroCore Inc.

    SCHEDULE 13G/A - electroCore, Inc. (0001560258) (Subject)

    11/13/25 2:27:02 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by electroCore Inc.

    10-Q - electroCore, Inc. (0001560258) (Filer)

    11/5/25 4:26:07 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on electroCore with a new price target

    HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

    1/19/22 6:31:24 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on electroCore with a new price target

    Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

    7/27/21 7:13:01 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on electroCore with a new price target

    Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

    3/13/21 8:17:18 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Goldberger Daniel S was granted 46,375 shares, increasing direct ownership by 16% to 338,940 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    1/28/26 4:30:05 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Lev Joshua S. was granted 27,889 shares, increasing direct ownership by 129% to 49,556 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    1/28/26 4:30:06 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Lev Joshua S. sold $12,625 worth of shares (2,500 units at $5.05), decreasing direct ownership by 10% to 21,667 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/5/25 4:15:45 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore to Participate at the 38th Annual Roth Conference

    ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference. Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth representative, or by emailing [email protected] for more information. About the Roth Capital Partners ConferenceThe Annual ROTH Conference is one of the largest in the nation for small-cap

    3/10/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026

    ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Thursday, March 19, 4:30 PM EDTDial-In: (646) 931-3860Webinar ID: 886 9421 4883Passcode: 014212Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc.electroCore, I

    3/9/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore's gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder ("PTSD")

    ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD. The study entitled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder," will be led by Danielle DeSouza MSc, PhD, VP of Research at Acacia Clinics ("the Investigator"). The study w

    1/21/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Errico Thomas J. bought $67,050 worth of shares (15,000 units at $4.47), increasing direct ownership by 6% to 281,401 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/13/25 6:05:11 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,230 worth of shares (1,000 units at $4.23), increasing direct ownership by 0.34% to 291,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/12/25 6:05:12 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Leadership Updates

    Live Leadership Updates

    View All

    electroCore Appoints Elena Bonfiglioli to Board of Directors

    ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling

    9/3/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Appoints James C. Theofilos to the Board of Directors

    ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. "I'm honored to have been appointed to the Board of Directors at electroCore," said Mr. Theofilos. "For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and founding partner. At Microsoft, I've had the privilege of serving as the global finance lead for our healthcare and life sciences business — working alongside some of the worl

    8/5/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Join Russell Microcap® Index

    ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

    6/11/24 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

    SC 13D/A - electroCore, Inc. (0001560258) (Subject)

    6/7/24 4:33:08 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

    SC 13G/A - electroCore, Inc. (0001560258) (Subject)

    2/14/24 3:15:55 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by electroCore Inc.

    SC 13D - electroCore, Inc. (0001560258) (Subject)

    12/18/23 4:10:26 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Financials

    Live finance-specific insights

    View All

    electroCore Announces Third Quarter 2025 Financial Results

    Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

    11/5/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Second Quarter 2025 Financial Results

    Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025  Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the three and six months ended June 30, 2025. Recent Highlights Record revenue for Q2'2025 of $7.4 million, a 20% increase over Q2'2024Year-to-Date revenue of $14.1 million, a

    8/6/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces First Quarter 2025 Financial Results

    First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

    5/7/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care